The NCI-MATCH study is now on hold during a pre-planned pause in enrollment. In this update, Dr. Barbara Conley (NCI-MATCH Study Chair) explains the trial's status and plans for its future.
The Budget Fact Book provides a summary of how NCI distributed its fiscal year 2014 $4.9 billion budget among its research programs. It also describes NCI funding policies related to research grant awards.
We've renamed our PDQ "Pain" summary and updated the information about how cancer pain is assessed, drugs used to relieve cancer pain, and treatment in older patients.
We've added the recent approval from the Food and Drug Administration (FDA) for the use of this drug to treat liposarcoma, a type of soft tissue sarcoma.
Eribulin mesylate (Halaven) was recently approved to treat liposarcoma. It is the first drug proven to help patients with liposarcoma live longer. Liposarcoma is a type of soft tissue sarcoma. Learn about the different types of soft tissue sarcoma and how they are treated.
This page lists incidence and mortality statistics for cancers that are diagnosed most often in the United States. We've recently updated the page with 2016 estimates.